Israel Englander Apellis Pharmaceuticals, Inc. Put Options Transaction History

Millennium Management LLC

  • $207 Billion
  • Q2 2024

Put Options

5 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$38.07 - $59.71 $2.19 Million - $3.43 Million
-57,400 Reduced 82.59%
12,100 $464,000
Q1 2024

May 15, 2024
BUY
$55.39 - $72.47 $2.58 Million - $3.38 Million
46,600 Added 203.49%
69,500 $4.09 Million
Q4 2023

Feb 14, 2024
SELL
$37.14 - $64.82 $48,282 - $84,265
-1,300 Reduced 5.37%
22,900 $1.37 Million
Q2 2023

Aug 14, 2023
BUY
$76.68 - $93.31 $1.86 Million - $2.26 Million
24,200 New
24,200 $2.2 Million
Q3 2022

Nov 14, 2022
BUY
$44.76 - $69.66 $3.58 Million - $5.57 Million
80,000 New
80,000 $5.46 Million

Others Institutions Holding APLS

# of Institutions
301
Shares Held
114M
Call Options Held
5.21M
Put Options Held
691K
View Full List

About Apellis Pharmaceuticals, Inc.

APLS Quotes by TradingView
  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.17B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email